Misonix Incorporated Participates In Cleveland Spine Review

FARMINGDALE, N.Y., July 12, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced its participation in the Cleveland Spine Review; Hands-On Course 2012, presented by the Cleveland Clinic Center for Spine Health, being held in Cleveland July 11-17, 2012.

The Cleveland Spine Review is a comprehensive bio-skills course utilizing the cadaver laboratory and didactic sessions while providing ample time for discussion. It is an intensive course that emphasizes the fundamentals of spine surgery through intensive, hands-on sessions, wherein the participants study surgical techniques and strategies for a range of procedures, including the most complex cases. More than 150 participants are expected to attend, including neurosurgeons, orthopedic surgeons, operating room nurses and physician assistants.

As a member of a select group of medical device manufacturers, Misonix will be exhibiting its innovative BoneScalpel Ultrasonic Bone Cutting System, which is being adopted by spine surgeons worldwide. Further, the BoneScalpel will be available for use by clinician registrants in the bio-skills laboratory sessions. Misonix personnel will be advising at multiple laboratory work stations to help surgeons understand the techniques necessary to enable them to perform faster and safer surgical procedures. Participants in the laboratory will be among the first surgeons to use the Company’s new 30mm Blade line extension, designed for precisely transecting larger bones and/or for providing deeper access into body cavities. Comments from surgeons currently using the BoneScalpel for their spine procedures include reference to the precise nature of the bone cuts, minimal bone loss, reduced bleeding, reduction in procedure time and a general feeling that the BoneScalpel provided an extra measure of safety.

The Cleveland Spine Review is one of more than 30 courses of a similar theme, throughout the United States, that will be supported by Misonix during the year.

As reported recently by Isador H. Lieberman, M.D., MBA, FRCSC and orthopedic surgeon at the Scoliosis & Spine Tumor Center, Texas Back Institute and Texas Health Presbyterian Hospital in Plano, TX, “The BoneScalpel is a safe and effective bone cutting device that can be used to facilitate osteotomies in a variety of spine surgeries. This device may obviate the need for and risk of high speed burrs and oscillating saws during spine surgery. It’s a very versatile and safe device, with multiple applications to carve and craft bone.”

The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps. To date, reported uses of the product in spine surgery include laminectomy, laminotomy, laminoplasty, corpectomy, spinal deformity, foraminotomy, facetectomy and other procedures performed by orthopedic and neuro surgeons.

“We are very pleased to continue to demonstrate our commitment to clinician education by participating in this unique event that brings together spine surgeons and affiliated personnel from around the United States and certain foreign countries,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “Being able to exhibit and demonstrate our state-of-the-art technology at this prestigious course exemplifies our determination to provide products to the medical community that can directly impact patient outcomes.”

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.